A 35-year-old woman with SLE presents with severe thrombocytopenia (platelet count 15,000/μL), hemolytic anemia (Hb 7.2 g/dL), and positive Coombs test. She has no renal involvement. What is the drug of choice for initial management of her lupus-related cytopenias?

Explanation

## Management of SLE-Associated Cytopenias **Key Point:** Corticosteroids are the first-line and drug of choice for lupus-related thrombocytopenia and hemolytic anemia. High-dose corticosteroids induce rapid platelet recovery and suppress hemolysis in the majority of patients. ### Rationale for Corticosteroids as First-Line 1. **Mechanism**: Suppress T-cell help to autoreactive B cells; reduce anti-platelet and anti-RBC antibody production 2. **Efficacy**: Achieve platelet response (>50,000/μL) in 70–80% of patients within 2–4 weeks 3. **Speed of Action**: Faster onset than immunosuppressive agents like cyclophosphamide 4. **Safety Profile**: Acceptable risk-benefit ratio for acute, severe cytopenias ### Typical Dosing for SLE Cytopenias - **Thrombocytopenia**: Prednisolone 0.5–1 mg/kg/day (or methylprednisolone 1 g IV daily × 3 days for severe cases) - **Hemolytic Anemia**: Prednisolone 0.5–1 mg/kg/day - **Taper**: Gradual reduction over 8–12 weeks once response achieved ### Treatment Hierarchy for SLE Cytopenias ```mermaid flowchart TD A[SLE with Severe Cytopenias]:::outcome --> B[High-dose Corticosteroids]:::action B --> C{Response at 2-4 weeks?}:::decision C -->|Yes| D[Taper Steroids Gradually]:::action C -->|No| E[Add Immunosuppressant]:::action E --> F{Agent Choice}:::decision F -->|Mild-moderate disease| G[Azathioprine or Mycophenolate]:::action F -->|Severe/Refractory| H[Cyclophosphamide or Rituximab]:::action D --> I[Maintenance: Low-dose Prednisolone]:::action H --> I G --> I ``` **High-Yield:** Corticosteroids are first-line for all SLE cytopenias. IVIG and rituximab are reserved for steroid-refractory cases. ### Comparison: Agents for SLE Cytopenias | Agent | Indication | Onset | Response Rate | Role | |-------|-----------|-------|---------------|------| | **Corticosteroids** | First-line | 2–4 weeks | 70–80% | Initial induction | | **IVIG** | Steroid-refractory, urgent | Days | 60–70% | Bridge therapy, acute | | **Rituximab** | Refractory, severe | 2–4 weeks | 50–60% | B-cell depletion, salvage | | **Cyclophosphamide** | Severe refractory | 4–8 weeks | 70–80% | Alkylating agent, salvage | | **Azathioprine** | Maintenance | 6–8 weeks | 60% | Steroid-sparing, chronic | **Clinical Pearl:** Although this patient has severe cytopenias (Hb 7.2, platelets 15,000), corticosteroids remain first-line because they work rapidly and are more effective than other agents for this specific manifestation. IVIG may be added if platelet count is <10,000/μL and bleeding risk is high, but it is not the primary drug of choice. **Warning:** Do not confuse lupus nephritis management (where cyclophosphamide is first-line) with cytopenia management (where corticosteroids are first-line). The organ system and manifestation determine the drug choice.